Neurocrine biosciences reports third quarter 2023 financial results and raises 2023 ingrezza sales guidance

Ingrezza® (valbenazine) third quarter net product sales of $486 million representing 29% year-over-year growth ingrezza® (valbenazine) 2023 net product sales guidance raised to $1.82 - $1.84 billion crinecerfont adult and pediatric cahtalysttm studies met primary endpoint and key secondary endpoints for the treatment of congenital adrenal hyperplasia analyst day on december 5th focused on r&d portfolio and strategy san diego , oct. 31, 2023 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced its financial results for the third quarter ended september 30, 2023, raised 2023 net sales guidance for ingrezza, and announced an analyst day to be held in new york city on december 5th. "with ingrezza sales continuing to grow, an expanded indication to treat chorea associated with huntington's disease, and positive phase 3 results in congenital adrenal hyperplasia, neurocrine remains well positioned to build a leading neuroscience-focused company," said kevin gorman, ph.d.
NBIX Ratings Summary
NBIX Quant Ranking